enGene Therapeutics (ENGN) Accounts Payables (2022 - 2026)
enGene Therapeutics (ENGN) posted quarterly Accounts Payables of $1.8 million for Q2 2026, up 14.42% year-over-year from $1.6 million in Q2 2025, and down 26.37% quarter-over-quarter from $2.4 million in Q1 2026.
enGene Therapeutics (ENGN) Accounts Payables (2022 - 2026) Analysis & Trends
enGene Therapeutics (ENGN) has reported Accounts Payables for 5 consecutive years, with $1.8 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Accounts Payables rose 14.42% year-over-year to $1.8 million; the TTM figure through Apr 2026 stood at $1.8 million (up 14.42% YoY), while the FY2025 annual figure was $6.7 million, up 373.99% from the prior year.
- Accounts Payables declined to $1.8 million in Q2 2026 per ENGN's latest filing, from $2.4 million in the prior quarter.
- Across five years, Accounts Payables topped out at $6.7 million in Q4 2025 and bottomed at $211000.0 in Q2 2024.
- Historically, Accounts Payables has averaged $2.1 million across 5 years, with a median of $1.7 million in 2025.
- On a YoY basis, Accounts Payables climbed as much as 642.65% in 2025 and fell as far as 16.7% in 2025.
- enGene Therapeutics' Accounts Payables stood at $723000.0 in 2022, then jumped by 59.89% to $1.2 million in 2023, then grew by 22.06% to $1.4 million in 2024, then soared by 373.99% to $6.7 million in 2025, then plunged by 73.19% to $1.8 million in 2026.
- Business Quant data shows ENGN's Accounts Payables at $1.8 million in Q2 2026, $2.4 million in Q1 2026, and $6.7 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 108.02 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 428.93 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 35.57 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 622.65 Mn |
| 10 | enGene Therapeutics | 124.11 Mn | 124.11 Mn | - | 1.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 1.79 Mn |
| Jan 31, 2026 | 2.44 Mn |
| Oct 31, 2025 | 6.69 Mn |
| Jul 31, 2025 | 2.38 Mn |
| Apr 30, 2025 | 1.57 Mn |
| Jan 31, 2025 | 2.61 Mn |
| Oct 31, 2024 | 1.41 Mn |
| Jul 31, 2024 | 2.86 Mn |
| Apr 30, 2024 | 211,000.00 |
| Jan 31, 2024 | 1.28 Mn |
| Oct 31, 2023 | 1.16 Mn |
| Oct 31, 2022 | 723,000.00 |